Jo Cox

Jo is an Executive Medical Director at tranScrip and brings over 20 years’ experience as a pharmaceutical physician. She has cross-functional leadership in clinical development, medical affairs and pharmacovigilance, across different therapy areas, with a particular focus on Women’s Health. Jo’s experience in global pharmacovigilance spans early and late phase oncology development. She was Safety Lead on regulatory submissions leading to successful approvals in US, Japan and Europe.

She is an ex-Medical Fellow at Eli Lilly and Co. in Global Oncology Clinical Development and Medical Lead on a global phase 3 study in early breast cancer – 5,600 patients at >600 sites in 38 countries.

Previously, Jo was a Global Oncology Patient Safety physician responsible for ongoing pharmacovigilance of oncology molecules in all phases of clinical development, and for global submission activities:

She provided medical input into the safety aspects of regulatory submissions in US, Europe, Japan.

Jo excels in the analysis and interpretation of safety data from phase 2 and 3 trials to co-author the Core Data Sheet and clinical safety sections of submission dossiers and Summary of Clinical Safety, Clinical Overview, Risk Management Plans.  Regulatory interactions, including presenting safety data to the FDA, EU Rapporteur and co-Rapporteur, responding to regulatory questions, and labelling negotiations.

In addition, Jo has recruited and managed medical teams of physicians, clinical research scientists and medical liaisons.

Jo’s clinical background is in Obstetrics and Gynaecology, primarily in the UK NHS, and 2 years spent in Australia. On joining Lilly UK, Jo worked in medical affairs on the women’s health portfolio, diabetes, urology and cardiovascular therapy areas, including product launches. Experience includes running Advisory Boards, publication strategy, medical input into promotional materials development and approval.

Jo is a member of the Royal College of Obstetricians and Gynaecologists, and the Faculty of Pharmaceutical Medicine Women and Children’s Health Expert Panel. Jo was previously a member of the NICE Guideline Review Panel for Women and Children’s Health, and the National Reproductive Health Research Network Board.